Findings showed DCCR significantly improved hyperphagia in patients with severe hyperphagia at baseline. The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...

Please provide your email address to receive an email when new articles are posted on . Diazoxide choline extended-release is the first FDA-approved therapy to address hyperphagia in Prader-Willi ...

Juliana Steffan's mother, April Steffan, created a YouTube video about Prader-Willi syndrome, a rare genetic disorder that causes a chronic feeling of hunger, among other physical, mental and ...

WE’LL TALK TO YOU LATER. WELL, IMAGINE EATING ENOUGH MAYBE TOO MUCH, BUT NEVER FEELING FULL. THAT’S WHAT A NORTHLAND TODDLER LIVES WITH EVERY DAY. AND THIS WORLD WHERE DISEASE DAY CAME DECISIONS DONNA ...

Soleno Therapeutics’ Vykat XR is now FDA approved for treating hyperphagia, or excessive hunger, in patients with Prader-Willi syndrome. The once-daily pill is the first approved therapy for this rare ...

Family genetics evaluations. Several family visits with the geneticist and subsequent laboratory evaluations revealed that Bobby had PWS. It was also established that his siblings did not have the ...

The European Medicines Agency (EMA) has validated the marketing authorisation application (MAA) submitted by Soleno Therapeutics for diazoxide choline prolonged-release tablets, aimed at treating ...

Children with Prader–Willi syndrome (PWS) receive growth-hormone (GH) replacement therapy. Small studies suggested that GH administration might also benefit adults with PWS; however, GH has multiple ...

The FDA granted priority review for a new drug application for an intranasal oxytocin analogue to reduce hyperphagia and behavioral distress associated with Prader-Willi syndrome, according to an ...

(RTTNews) - There are some diseases/disorders which lack a cure and Prader-Willi Syndrome is one of them. Prader-Willi Syndrome, or PWS, is a rare genetic condition that affects one in 12,000 to ...

Duke Health researchers have identified a drug-like small molecule that, in animal experiments, appears to be an effective treatment for a genetic disorder called Prader-Willi syndrome. Prader-Willi ...

Acadia Pharma (NASDAQ:ACAD) shares fell in the premarket on Wednesday after the biotech announced that its experimental therapy for a rare genetic condition known as Prader-Willi syndrome failed in a ...